VolitionRx (NYSE:VNRX) Trading Down 4.3% - What's Next?

Key Points

• VolitionRx's stock price fell by 4.3% to $0.64 amid increased trading volume, marking a decline from its previous close of $0.67.
• Analysts have set various price targets for VolitionRx, with Jones Trading upgrading to a "strong-buy" at $3.00, while others have issued a "sell" rating, reflecting mixed sentiments in the market.
• Insider trading activity was noted, with CEO Cameron John Reynolds and Director Guy Archibald Innes each purchasing 78,125 shares at $0.64, indicating growing confidence in the company's potential.

VolitionRx Limited (NYSE:VNRX - Get Free Report)'s stock price traded down 4.3% during trading on Thursday . The stock traded as low as $0.63 and last traded at $0.64. 199,690 shares traded hands during mid-day trading, an increase of 2% from the average session volume of 196,287 shares. The stock had previously closed at $0.67.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Jones Trading upgraded shares of VolitionRx to a "strong-buy" rating and set a $3.00 target price for the company in a research report on Tuesday, June 10th. D. Boral Capital reissued a "buy" rating and set a $5.00 target price on shares of VolitionRx in a research note on Thursday, July 17th. Finally, Wall Street Zen assumed coverage on VolitionRx in a research note on Thursday, May 15th. They set a "sell" rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, VolitionRx has a consensus rating of "Moderate Buy" and an average target price of $3.50.

VolitionRx Trading Up 2.7%

The firm has a 50-day moving average of $0.69 and a 200 day moving average of $0.59. The company has a market cap of $66.24 million, a P/E ratio of -1.77 and a beta of 1.26.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes bought 78,125 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the transaction, the director directly owned 966,814 shares of the company's stock, valued at approximately $618,760.96. The trade was a 8.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cameron John Reynolds purchased 78,125 shares of VolitionRx stock in a transaction that occurred on Tuesday, August 5th. The stock was acquired at an average cost of $0.64 per share, with a total value of $50,000.00. Following the transaction, the chief executive officer owned 2,609,847 shares in the company, valued at $1,670,302.08. This trade represents a 3.09% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 258,750 shares of company stock worth $148,475 in the last quarter. 10.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On VolitionRx

A number of hedge funds and other institutional investors have recently made changes to their positions in VNRX. Blair William & Co. IL bought a new stake in shares of VolitionRx during the second quarter valued at about $30,000. Silverberg Bernstein Capital Management LLC raised its stake in VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after purchasing an additional 60,209 shares in the last quarter. Millennium Management LLC purchased a new stake in VolitionRx in the fourth quarter valued at approximately $36,000. Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Finally, Northern Trust Corp raised its stake in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.